Literature DB >> 22161222

Design of pharmacokinetic studies for latent covariates.

Chakradhar V Lagishetty1, Carolyn V Coulter, Stephen B Duffull.   

Abstract

Latent covariates are covariates that are known to exist but are either observable but unavailable or unobservable at the time of the clinical study. Designs to account for latent covariates must incorporate both uncertainty in the prevalence of the covariate and the data-type of the covariate. The informativeness of the covariate will then depend on whether the covariate data is continuous, ordinal or nominal. In this work we consider designs for latent covariates that may either directly influence the parameter of interest, or indirectly via actions on an observable covariate which then influences the parameter of interest. We consider a motivating example based on the effect of a genetic polymorphism on the influence of a continuous covariate (age) on drug clearance (CL). The polymorphism could take the case of a haplotype with many variant alleles, or a copy number variation in genes with different phenotypic expressions which could be treated as continuous data, or as a bi- or tri-allelic single nucleotide polymorphism that could form either an ordinal or nominal covariate on drug CL. The aim of this study was to investigate designs for clinical studies for latent covariates that accommodate both unknown prevalence and unknown data-type. Initially, the informativeness of a covariate was explored using linear regression assuming the three data-types continuous, ordinal and nominal. The linear covariate model was then considered within a nonlinear mixed effects modelling framework. Two simulation scenarios were considered: (1) the influence of the latent covariate directly on the parameter of interest and (2) the influence of the latent covariate on an observable non-latent continuous covariate, which was assumed to follow a normal or stratified distribution, and the effect of this covariate on the parameter of interest. A power analysis for population PK modelling (1) where the latent covariate had direct influence on the parameter also showed similar behaviour to the linear regression solution. When the influence of the latent covariate was mediated via another observable non-latent continuous covariate, the power for the continuous model was highest but the power of the ordinal model was indistinguishable from that of the nominal model. Stratification of the observable non-latent continuous covariate did not appreciably change the power to identify the latent covariate from that when we assumed the observable covariate conformed to a normal distribution. It was found that parameter estimation is generally at least 1.5 to 7 fold more precise for continuous models than for categorical models.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22161222     DOI: 10.1007/s10928-011-9231-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  13 in total

1.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

2.  Assessment of type I error rates for the statistical sub-model in NONMEM.

Authors:  Ulrika Wählby; M René Bouw; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

3.  Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.

Authors:  Jakob Ribbing; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

4.  Evaluation of type I error rates when modeling ordered categorical data in NONMEM.

Authors:  Ulrika Wählby; Katalin Matolcsi; Mats O Karlsson; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

5.  Covariate detection in population pharmacokinetics using partially linear mixed effects models.

Authors:  Peter L Bonate
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

6.  Informative study designs to identify true parameter-covariate relationships.

Authors:  Phey Yen Han; Carl M J Kirkpatrick; Bruce Green
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-03-27       Impact factor: 2.745

7.  Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.

Authors:  Julie Bertrand; Emmanuelle Comets; France Mentre
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

8.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Authors:  Julie Bertrand; Emmanuelle Comets; Céline M Laffont; Marylore Chenel; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-27       Impact factor: 2.745

9.  Statistical evaluation of clinical trial design for a population pharmacokinetic study--a case study.

Authors:  Susumu Nakade; Atsushi Nishibori; Hiroyuki Okamoto; Shun Higuchi
Journal:  Drug Metab Pharmacokinet       Date:  2004-10       Impact factor: 3.614

10.  Common variants near TERC are associated with mean telomere length.

Authors:  Veryan Codd; Massimo Mangino; Pim van der Harst; Peter S Braund; Michael Kaiser; Alan J Beveridge; Suzanne Rafelt; Jasbir Moore; Chris Nelson; Nicole Soranzo; Guangju Zhai; Ana M Valdes; Hannah Blackburn; Irene Mateo Leach; Rudolf A de Boer; Masayuki Kimura; Abraham Aviv; Alison H Goodall; Willem Ouwehand; Dirk J van Veldhuisen; Wiek H van Gilst; Gerjan Navis; Paul R Burton; Martin D Tobin; Alistair S Hall; John R Thompson; Tim Spector; Nilesh J Samani
Journal:  Nat Genet       Date:  2010-02-07       Impact factor: 38.330

View more
  3 in total

1.  Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research.

Authors:  Chiara Piana; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

2.  Population pharmacokinetics of sildenafil in extremely premature infants.

Authors:  Daniel Gonzalez; Matthew M Laughon; P Brian Smith; Shufan Ge; Namasivayam Ambalavanan; Andrew Atz; Gregory M Sokol; Chi D Hornik; Dan Stewart; Gratias Mundakel; Brenda B Poindexter; Roger Gaedigk; Mary Mills; Michael Cohen-Wolkowiez; Karen Martz; Christoph P Hornik
Journal:  Br J Clin Pharmacol       Date:  2019-12-15       Impact factor: 3.716

3.  Quantification of the Forgiveness of Drugs to Imperfect Adherence.

Authors:  P Assawasuwannakit; R Braund; S B Duffull
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-03-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.